$\sim$ 

## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287

to Section 16.	t if no longer subje Form 4 or Form 5 y continue. <i>See</i> ).		Filed pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
1. Name and Adda <u>Wallace Peg</u> (Last) C/O COGNITT 2500 WESTCI	(First)	(Middle) PEUTICS, INC.	2. Issuer Name and Ticker or Trading Symbol <u>COGNITION THERAPEUTICS INC</u> [ CGTX ] 3. Date of Earliest Transaction (Month/Day/Year) 09/27/2022	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below)				
(Street) PURCHASE (City)	NY (State)	10577 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	1	nt/Group Filing (C I by One Reportin I by More than Or	ng Person		
		Table I - Non-Dei	rivative Securities Acquired. Disposed of, or Ben	eficially Owned				

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code ( 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1150. 4)
Common Stock	09/27/2022		J		22,461(1)	A	<b>\$</b> 0	25,461	D	

			I												
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities)															
Derivative Conversion Date		3. Transaction Date (Month/Day/Year)	Transaction ate Ionth/Day/Year) 3A. Deemed Execution Date, if any		4. Transaction Code (Instr. 8)		umber vative urities uired r osed ) r. 3, 4 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. Represents shares of common stock distributed to the Reporting Person from Golden Seeds Cognition Therapeutics, LLC for no consideration.

## Peggy Wallace

09/29/2022 Date

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.